ThromboGenics announced data from two Phase 3 clinical trials evaluating ocriplasmin for the treatment of vitreomacular traction (VMT) and macular holes. The studies highlight that a single ...

Both studies met their primary endpoint and demonstrated that JETREA® successfully resolved VMT and macular holes compared to placebo. At day 28, 26.5% Jetrea-treated patients achieved resolution ...

The paper highlights that a single intravitreal injection of ocriplasmin resolved Vitreomacular Adhesion (VMA), releasing traction and closing macular holes in significantly more patients than placebo ...

The pivotal studies, published in the New England Journal of Medicine, showed that patients who were treated with Jetrea successfully achieved resolution of VMT and closure of macular holes as ...

VMT itself may be associated with epiretinal membrane formation and the development of idiopathic macular holes (IMH). Such pathologies may cause visual disturbances, including metamorphopsia ...